After facing a delayed decision deadline and a clinical hold, Regenxbio’s Hunter syndrome gene therapy has been rejected by the FDA. In rejecting RGX-121, the FDA raised concerns about its clinical ...
Objective Cardiovascular diseases (CVD) remain the leading cause of mortality globally, necessitating early risk identification to improve prevention and management strategies. Traditional risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results